Free Trial
NASDAQ:CAPS

Capstone Therapeutics Q1 2026 Earnings Report

Capstone Therapeutics logo
$0.37 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$0.36 -0.01 (-3.51%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Capstone Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.13
Beat/Miss
N/A
One Year Ago EPS
N/A

Capstone Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$12.51 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Capstone Therapeutics Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Capstone Therapeutics Earnings Headlines

Capstone Therapeutics (CAPS) to Release Earnings on Thursday
Read this warning immediately
Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
Capstone Holding Stock Price History
See More Capstone Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Capstone Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capstone Therapeutics and other key companies, straight to your email.

About Capstone Therapeutics

Capstone Therapeutics (NASDAQ:CAPS), a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

View Capstone Therapeutics Profile